Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 1.23% and Operating profit at 34.47% over the last 5 years
2
The company has declared Negative results for the last 6 consecutive quarters
3
With ROE of 4.51%, it has a fair valuation with a 1.18 Price to Book Value
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 13,829 Million (Large Cap)
26.00
NA
4.43%
-0.40
6.14%
1.22
Revenue and Profits:
Net Sales:
1,383 Million
(Quarterly Results - Sep 2025)
Net Profit:
181 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.99%
0%
-1.99%
6 Months
3.79%
0%
3.79%
1 Year
7.89%
0%
7.89%
2 Years
-24.25%
0%
-24.25%
3 Years
-45.65%
0%
-45.65%
4 Years
-50.96%
0%
-50.96%
5 Years
-43.01%
0%
-43.01%
By-health Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
1.23%
EBIT Growth (5y)
34.47%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.40
Sales to Capital Employed (avg)
0.63
Tax Ratio
29.36%
Dividend Payout Ratio
92.88%
Pledged Shares
0
Institutional Holding
0.02%
ROCE (avg)
21.48%
ROE (avg)
14.00%
Valuation key factors
Factor
Value
P/E Ratio
26
Industry P/E
Price to Book Value
1.18
EV to EBIT
13.05
EV to EBITDA
9.10
EV to Capital Employed
1.31
EV to Sales
1.46
PEG Ratio
NA
Dividend Yield
4.64%
ROCE (Latest)
10.06%
ROE (Latest)
4.51%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Sideways
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot : Jun 2017
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.02%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
1,383.10
1,120.30
23.46%
Operating Profit (PBDIT) excl Other Income
152.80
-9.30
1,743.01%
Interest
2.80
7.20
-61.11%
Exceptional Items
14.70
3.70
297.30%
Consolidate Net Profit
180.80
-18.00
1,104.44%
Operating Profit Margin (Excl OI)
110.50%
-65.80%
17.63%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is 23.46% vs -48.76% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is 1,104.44% vs -104.96% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
6,805.50
9,313.70
-26.93%
Operating Profit (PBDIT) excl Other Income
998.80
2,098.40
-52.40%
Interest
13.80
4.70
193.62%
Exceptional Items
28.00
50.60
-44.66%
Consolidate Net Profit
647.90
1,778.80
-63.58%
Operating Profit Margin (Excl OI)
109.20%
199.10%
-8.99%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -26.93% vs 19.42% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -63.58% vs 26.04% in Dec 2023
About By-health Co., Ltd. 
By-health Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






